Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Quarterly results
Appointed director
|
|
Surface Oncology, Inc. (SURF)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/11/2023 |
4
| Adams Chandra (Deputy GC) has filed a Form 4 on Surface Oncology, Inc.|
Txns:
| Sold 3,901 shares
@ $0.94, valued at
$3.7k
|
|
| 08/11/2023 |
4
| FEES JESSICA (CFO) has filed a Form 4 on Surface Oncology, Inc.|
Txns:
| Sold 9,434 shares
@ $0.94, valued at
$8.9k
|
|
| 08/11/2023 |
4
| ONEILL ALISON (Chief Medical Officer) has filed a Form 4 on Surface Oncology, Inc.|
Txns:
| Sold 7,042 shares
@ $0.94, valued at
$6.6k
|
|
| 08/11/2023 |
4
| ROSS ROBERT W. (CEO) has filed a Form 4 on Surface Oncology, Inc.|
Txns:
| Sold 16,713 shares
@ $0.94, valued at
$15.7k
|
|
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
8-K
| Quarterly results |
| 07/26/2023 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 07/20/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/12/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 07/12/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 07/07/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 07/03/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/16/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/16/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/16/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/16/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/16/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/16/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/16/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/16/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/16/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/16/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/16/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/16/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/16/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/16/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/16/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 06/16/2023 |
8-K
| Amended existing or entered into new employment agreement with an officer|
Docs:
|
"Agreement and Plan of Merger, by and among Surface Oncology, Inc., Coherus BioSciences, Inc., Crimson Merger Sub I, Inc. and Crimson Merger Sub II, LLC, (Form of CVR Agreement included as Exhibit A thereto)",
"Form of Executive Agreement Amendment",
"Form of C-Suite Executive Agreement Amendment",
"Form of Retention Agreement",
"Coherus to Acquire Surface Oncology" |
|
| 06/16/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 03/09/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/09/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
|
|
|